

# Karen E Sheppard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735470/publications.pdf>

Version: 2024-02-01

80  
papers

3,639  
citations

172457

29  
h-index

138484

58  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	9.4	242
2	The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 5320-5328.	7.0	226
3	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 69-95.	0.4	204
4	An activating <i>Pik3ca</i> mutation coupled with <i>Pten</i> loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 553-557.	8.2	174
5	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. <i>PLoS ONE</i> , 2011, 6, e18064.	2.5	172
6	Loss of <i>CDKN2A</i> expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <i>CDK4/6</i> inhibitor <i>PD0332991</i> in melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 590-600.	3.3	165
7	Adrenocortical Steroids and the Brain. <i>Annual Review of Physiology</i> , 1987, 49, 397-411.	13.1	132
8	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. <i>Cancer Discovery</i> , 2019, 9, 1036-1049.	9.4	129
9	Second AKT: The rise of SGK in cancer signalling. <i>Growth Factors</i> , 2010, 28, 394-408.	1.7	127
10	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. <i>Science Signaling</i> , 2011, 4, ra56.	3.6	126
11	The type I and type II $11\beta$ -hydroxysteroid dehydrogenase enzymes. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999, 69, 391-401.	2.5	122
12	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. <i>Science Signaling</i> , 2015, 8, ra82.	3.6	114
13	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. <i>Cancer Research</i> , 2012, 72, 4060-4073.	0.9	100
14	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016, 7, 49800-49818.	1.8	93
15	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2020, 11, 2641.	12.8	90
16	Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17990-18000.	7.1	81
17	Regression of pressure overload-induced left ventricular hypertrophy in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H2702-H2707.	3.2	79
18	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. <i>Cancer Management and Research</i> , 2013, 5, 281.	1.9	73

#	ARTICLE	IF	CITATIONS
19	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013, 49, 3936-3944.	2.8	72
20	Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: Direct binding studies. <i>The Journal of Steroid Biochemistry</i> , 1987, 28, 737-742.	1.1	65
21	11 $\beta$ -Hydroxysteroid Dehydrogenase 1 Transforms 11-Dehydrocorticosterone into Transcriptionally Active Glucocorticoid in Neonatal Rat Heart. <i>Endocrinology</i> , 2002, 143, 198-204.	2.8	65
22	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021, 11, 2582-2601.	9.4	62
23	Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1. <i>Cardiovascular Research</i> , 2006, 70, 555-565.	3.8	60
24	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <i>International Journal of Cancer</i> , 2018, 142, 2139-2152.	5.1	56
25	Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1411-1421.	7.0	52
26	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. <i>Scientific Reports</i> , 2013, 3, 3494.	3.3	44
27	Differential Regulation of Type II Corticosteroid Receptor Messenger Ribonucleic Acid Expression in the Rat Anterior Pituitary and Hippocampus*. <i>Endocrinology</i> , 1990, 127, 431-439.	2.8	43
28	Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. <i>Oncotarget</i> , 2016, 7, 46492-46508.	1.8	40
29	Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. <i>Oncotarget</i> , 2015, 6, 1115-1127.	1.8	40
30	ON THE MECHANISM OF ACTION OF ALDOSTERONE. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1969, 64, 330-337.	7.1	29
31	UTP Transactivates Epidermal Growth Factor Receptors and Promotes Cardiomyocyte Hypertrophy Despite Inhibiting Transcription of the Hypertrophic Marker Gene, Atrial Natriuretic Peptide. <i>Journal of Biological Chemistry</i> , 2004, 279, 8740-8746.	3.4	29
32	Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?. <i>Cancers</i> , 2020, 12, 1583.	3.7	29
33	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	4.8	29
34	Corticosteroid Receptors, 11 $\beta$ -Hydroxysteroid Dehydrogenase, and the Heart. <i>Vitamins and Hormones</i> , 2003, 66, 77-112.	1.7	27
35	II. Intestinal corticosteroid receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G742-G746.	3.4	26
36	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1495-1503.	4.1	26

#	ARTICLE	IF	CITATIONS
37	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 616-627.	6.4	26
38	Corticotrope responsiveness to glucocorticoids is modulated via rapid CRF-mediated induction of the proto-oncogene c-fos. <i>Molecular and Cellular Endocrinology</i> , 1993, 94, 111-119.	3.2	25
39	Adrenocorticotropin-Releasing Factor Down-Regulates Glucocorticoid Receptor Expression in Mouse Corticotrope Tumor Cells via an Adenylate Cyclase-Dependent Mechanism*. <i>Endocrinology</i> , 1991, 129, 663-670.	2.8	23
40	Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1987, 252, E224-E229.	3.5	21
41	Type I receptors in parotid, colon, and pituitary are aldosterone selective in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1987, 253, E467-E471.	3.5	18
42	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	3.3	16
43	Corticosteroid receptors and 11 $\beta$ -hydroxysteroid dehydrogenase isoforms in rat intestinal epithelia. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G541-G547.	3.4	15
44	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 568.	3.7	15
45	11 $\beta$ -Hydroxysteroid Dehydrogenase 1 Transforms 11-Dehydrocorticosterone into Transcriptionally Active Glucocorticoid in Neonatal Rat Heart. <i>Endocrinology</i> , 2002, 143, 198-204.	2.8	15
46	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. <i>Gene</i> , 2017, 612, 36-48.	2.2	14
47	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies. <i>Cancers</i> , 2021, 13, 5810.	3.7	14
48	Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells.. <i>Endocrinology</i> , 1995, 136, 3707-3713.	2.8	13
49	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. <i>Npj Precision Oncology</i> , 2022, 6, 26.	5.4	13
50	Specific nuclear localization of 11-dehydrocorticosterone in rat colon: evidence for a novel corticosteroid receptor.. <i>Endocrinology</i> , 1996, 137, 3274-3278.	2.8	12
51	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 136-146.	3.4	12
52	PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5136.	3.7	11
53	Decreased apparent affinity of corticosterone for colonic crypt glucocorticoid receptors is dependent on the cellular milieu and is distinct from corticosterone metabolism. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 64, 35-42.	2.5	10
54	Is resistance to targeted therapy in cancer inevitable?. <i>Cancer Cell</i> , 2021, 39, 1047-1049.	16.8	10

#	ARTICLE	IF	CITATIONS
55	Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma.. Journal of Clinical Oncology, 2012, 30, 8520-8520.	1.6	10
56	Cortisol 17 <sup>β</sup> acid, transcortin, and the heterogeneity of rat brain glucocorticoid receptors. The Journal of Steroid Biochemistry, 1986, 25, 285-288.	1.1	9
57	Glucocorticoid Receptor Function in Rat Pituitary Intermediate Lobe is Inhibited by an Endogenous Protein. Journal of Neuroendocrinology, 1993, 5, 195-200.	2.6	9
58	Cyclosporin A and FK506 are Potent Activators of Proopiomelanocortin-Derived Peptide Secretion Without Affecting Corticotrope Glucocorticoid Receptor Function. Journal of Neuroendocrinology, 1995, 7, 833-840.	2.6	9
59	Calcium and protein kinase C regulation of the glucocorticoid receptor in mouse corticotrope tumor cells. Journal of Steroid Biochemistry and Molecular Biology, 1994, 48, 337-345.	2.5	8
60	CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway. Cancers, 2021, 13, 524.	3.7	8
61	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. Nature Communications, 2022, 13, 1100.	12.8	8
62	cAMP modulates glucocorticoid-induced protein accumulation and glucocorticoid receptor in cardiomyocytes. American Journal of Physiology - Endocrinology and Metabolism, 1996, 271, E827-E833.	3.5	6
63	Novel nuclear corticosteroid binding in rat small intestinal epithelia. American Journal of Physiology - Renal Physiology, 2000, 279, G536-G542.	3.4	5
64	Unexpected role of CDK4 in a G2/M checkpoint. Cell Cycle, 2015, 14, 1351-1352.	2.6	5
65	CDK4/6 inhibition in cancer: the cell cycle splicing connection. Molecular and Cellular Oncology, 2019, 6, e1673643.	0.7	5
66	Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells. Endocrinology, 1995, 136, 3707-3713.	2.8	5
67	Specific nuclear localization of 11-dehydrocorticosterone in rat colon: evidence for a novel corticosteroid receptor. Endocrinology, 1996, 137, 3274-3278.	2.8	5
68	Steroid specificity of the putative DHB receptor: evidence that the receptor is not 11 <sup>β</sup> HSD. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E124-E131.	3.5	4
69	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. Cancers, 2021, 13, 6342.	3.7	4
70	Abstract 3416: Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.. , 2013, , .		2
71	Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAFV600 melanoma cells. Scientific Data, 2020, 7, 339.	5.3	1
72	Abstract 2826: Sustained melanoma regression is achieved with continuous palbociclib and PLX4720 treatment but not with intermittent or sequential dosing. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
73	Abstract 4130: Genomic profiling of ovarian tumor cell lines provides a predictive signature of sensitivity to PF-4691502, a dual PI3kinase and mTOR inhibitor. , 2010, , .		0
74	Abstract 4289: Using the right tools: A catalog of ovarian cancer cell lines by subtype. , 2011, , .		0
75	Abstract 2718: Targeting ribosome biogenesis with CX5461 as a potential treatment for melanoma and ovarian cancer. , 2014, , .		0
76	Abstract B05: Targeting BRAF and CDK4 in BRAF mutant melanoma induces sustained tumor regression. , 2015, , .		0
77	Abstract 3089: CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma. , 2015, , .		0
78	Abstract 2687: Receptor tyrosine kinases can mediate compensatory signaling and phenotype-switching associated with resistance to BRAF inhibitors. , 2015, , .		0
79	Abstract A24: A genome-wide RNAi screen identifies synthetic lethality of CX-5461 with homologous recombination repair deficiency in ovarian cancer. , 2017, , .		0
80	Abstract A061: Targeting PRMT5 enhances the response to CDK4/6 inhibitors in multiple cancer types. , 2019, , .		0